Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PRUNE1 | Q86TP1 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.32 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14324954 | 1.00 | ALDH1A1 (0.36) | ALDH1A1TP53MAPTTDP1PRUNE1 | |
| SCHEMBL14321924 | 0.86 | ALDH1A1 (0.39) | ALDH1A1TP53MAPTTDP1PRUNE1 | |
| SCHEMBL14321926 | 0.86 | ALDH1A1 (0.39) | ALDH1A1TP53MAPTTDP1PRUNE1 | |
| SCHEMBL14322063 | 0.80 | TP53 (0.35) | ALDH1A1TP53MAPTTDP1GSK3B | |
| SCHEMBL14322062 | 0.80 | TP53 (0.35) | ALDH1A1TP53MAPTTDP1GSK3B | |
| SCHEMBL9396 | 0.79 | BACE1 (0.48) | ALDH1A1TP53 | |
| SCHEMBL9397 | 0.79 | BACE1 (0.48) | ALDH1A1TP53 | |
| SCHEMBL13635 | 0.71 | MEN1 (0.43) | ALDH1A1TP53MAPTTDP1PRUNE1 | |
| SCHEMBL9404 | 0.71 | MEN1 (0.43) | ALDH1A1TP53MAPTTDP1PRUNE1 | |
| SCHEMBL9405 | 0.71 | MEN1 (0.43) | ALDH1A1TP53MAPTTDP1PRUNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | ALDH1A1 1846/4885TP53 2390/4885MAPT 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.